medigraphic.com
ISSN 1561-2937 (Print)

2016, Number 1

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2016; 22 (1)

Pericardial disease by mycobacterium tuberculosis and pulmonary embolism in patients with immune failure case report and review of literature

Álvarez TLC, Ruiz FA, Flores LEN

Language: Spanish
References: 15
Page: 43-46
PDF size: 298.96 Kb.


ABSTRACT

Tuberculosis remains a major public health problem, the incidence of this disease is higher than other countries. The incidence varies widely in Latin America it is estimated that going from 0.5% to 1.5%. Specifically in Mexico a mortality rate of 3.9 per 100 000 population is reported. The growing number of cases despite health programs is paradoxical. The most important factor appears to be the increasing number of carriers of the acquired immunodeficiency syndrome. It has been reported in Mexican literature that 11% of AIDS patients suffer simultaneously from tuberculosis. Mortality in untreated tuberculous pericarditis is close to 85% pericardial involvement of this entity is rare and often difficult to diagnose. The incidence of pericarditis in patients with pulmonary tuberculosis is estimated 1-8%. The onset of the disease may be acute, with cough, dyspnea, chest pain, lower limb edema, fever (usually less than 39 degrees) tachycardia, and diaphoresis. Traditionally you can show pericardial rub, hepatomegaly, ascites, decreased heart sounds. Represents 4% of acute pericarditis, 7% of cases of cardiac tamponade and constrictive pericarditis 6%.


REFERENCES

  1. Bongani M. Mayosi,Lesley. JBurgess and Anton F.Doubell Tuberculous Pericarditis. Circulation.2005;112:36083616.

  2. Barbara W. Trautner and Rabih O. Darouiche.Tuberculous Pericarditis: Optimal Diagnosis and Management. Clinical Infectious Diseases 2001;33:954–61.

  3. John Wiley & Sons,Ltd.Interventions for treating tuberculous pericarditis 2009. Published by The Cochrane Collaboration.

  4. Aguilar JA, Summerson C, González ME et al. “Pericarditis Tuberculosa. Experiencia de 10 años”. Arch Cardiol Mex 2007;77: 209-21

  5. Eisenberg MJ, Gordon AS, Schiller NB. “HIV-associated pe-ricardial effusions”. Chest 1992;102:956-58.

  6. Mayosi BM, Wiysonge CS, Ntsekhe et al. « Clinical charac-teristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Manage-ment of Pericarditis in Africa (IMPI Africa) registry”. BMC Infect Dis 2006;6(2):1-9

  7. Montuschi E, Reeves T. “Tuberculous Pericardi-tis.Correspondence”. BMJ 1947; (May 17):693.

  8. Syed F, Mayosi B. “A Modern Approach to Tuberculous Pe-ricarditis”. Prog Cardiovasc Dis 2007;50(3):218-36.

  9. Hakim JG, Ternouth I, Mushangi E et al. “Double blind ran-domized placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients”. Heart 2000;84(2):183-88.

  10. Saber AA, Aboolian A, La Raja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am-Surg.2001;67:645-7.

  11. Copur AS, Smith PR, Gómez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS. 2002;16:205-9.

  12. Kelley MA, Abbuhl S. Massive pulmonary embolism. Clin Chest Med. 1994;15:547-60.

  13. Moser KM. Venous thromboembolism. Am Rev Respir Dis. 1990;141:235-49.

  14. Rocha E, Panizo C, Lecumberri R. Treatment of venous thromboembolism. Med Clin (Barc).2000;115:224-35.

  15. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest. 1999;115:1695-707.




2020     |     www.medigraphic.com